SLC5A2 and heart failure: Furthermore, beyond and independent of glycaemic control, clinical trials using SGLT2 inhibitors have demonstrated unprecedented cardio-renal benefits such as significantly reduced CV morbidity and mortality, lower rates of hospitalized heart failure, improved renal function and reduced progression of diabetic nephropathy [20, 28, 29••, 30, 31] (Fig. 1).